International Biotechnology Trust’s Aurinia Pharmaceuticals AUPH Stock Holding History

International Biotechnology Trust’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$8.07M	Buy	1,040,530 +467,000	+81%	+$4.57M	2.72%	13
2023 Q2	$5.55M	Hold	573,530	–	–	1.69%	20
2023 Q1	$6.28M	Hold	573,530	–	–	1.75%	19
2022 Q4	$2.48M	Hold	573,530	–	–	0.77%	31
2022 Q3	$4.31M	Buy	573,530 +567,772	+9,861%	+$4.91M	1.38%	25
2022 Q2	$574K	Sell	5,758 -429,242	-99%	-$4.8M	5.98%	2
2022 Q1	$3.96M	Buy	435,000 +100,500	+30%	+$1.55M	0.89%	31
2021 Q4	$7.65M	Buy	334,500 +211,000	+171%	+$5M	1.7%	22
2021 Q3	$2.72M	Sell	123,500 -175,000	-59%	-$2.78M	0.66%	34
2021 Q2	$3.87M	Hold	298,500	–	–	1.02%	25
2021 Q1	$3.88M	Buy	298,500 +220,000	+280%	+$3.19M	1.02%	26
2020 Q4	$1.08M	Sell	78,500 -36,500	-32%	-$531K	0.3%	43
2020 Q3	$1.69M	Buy	+115,000	New	+$1.67M	0.55%	32

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

International Biotechnology Trust's AUPH Position: Q3 2023 in Review

International Biotechnology Trust increased its Aurinia Pharmaceuticals (AUPH) stake by 81% in Q3 2023, buying an estimated $4.57M and bringing the position to 1,040,530 shares worth $8.07M. The position accounts for 2.72% of the portfolio, ranked #13.

International Biotechnology Trust first reported a position in AUPH in Q3 2020 and has held it in 13 quarters since. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2023.

International Biotechnology Trust held 1,040,530 shares of Aurinia Pharmaceuticals worth $8.07M as of Q3 2023.
International Biotechnology Trust bought 467,000 Aurinia Pharmaceuticals shares in Q3 2023, an estimated $4.57M.
Aurinia Pharmaceuticals made up 2.72% of International Biotechnology Trust's portfolio in Q3 2023, its #13 holding.
International Biotechnology Trust first reported a position in Aurinia Pharmaceuticals in Q3 2020 and has held it in 13 quarters since.
198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.